Nivolumab-ipilimumab for previously untreated advanced hepatocellular carcinoma

Nivolumab and ipilimumab is in development for the first-line treatment of advanced hepatocellular carcinoma (HCC). HCC is the most common type of primary liver cancer, which affects men more than women, and is more likely to develop the older a person gets. Advanced HCC means the cancer is incurable. Symptoms include weight loss, jaundice (yellowing of skin), itching, nausea (feeling sick), bloating of the abdomen, loss of appetite, feeling full after eating small amounts, abdomen pain and a lump on the right side of the abdomen. There is a need for treatment options for advanced HCC, as there are currently limited first-line options.